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Abstract 
 According to prevalence of obesity and its-associated 
metabolic disorders worldwide, these diseases become severe and 
global health problem. Obesity defined as a condition accumulated 
excess fat mass bodily is a hall marker and major cause of metabolic 
diseases such as cardiovascular disease, stroke, and type 2 diabetes 
(T2D). Because obesity and T2D patients have dramatically higher 
risks of cardiovascular disease, the most common cause of death in 
Western countries, an increase in the prevalence of obesity and diabetes 
in the population is one of the most serious problems of modern society. 
Thus, the prevention and treatment of obesity and T2D become more 
and more important. Insulin resistance, an attenuated or lack of 
response of the insulin receptor (IR) and its downstream signaling 
pathway to insulin stimulation even at high doses of insulin, is a 
representative characteristic of T2D. Although insulin resistance is 
caused by inflammation, oxidative stress, ER stress, and mitochondrial 
dysfunction, the specific mechanisms which lead from obesity to T2D 
is still unclear.  
 ii 
Recent evidences have been clearly showed that capsaicin, a 
pungent component of chili peppers, play a crucial role in obesity and 
metabolic disorders. Administration of capsaicin prevents obesity and 
improves glucose homeostasis and insulin secretion in small rodents 
and humans. Several previous studies have reported supportive clinical 
evidence that consumption of red peppers or capsaicin was shown to 
decrease appetite, cause weight loss and stimulate thermogenesis 
caused by substrate oxidation from carbohydrate to fat oxidation. 
However, the role of its receptor, transient receptor potential vanilloid 
subfamily type 1 (TRPV1), in development of obesity and its-
associated insulin resistance is controversial, which suggests that its 
specific function and mechanistic studies in metabolic disorders are 
poorly understood.  
Here, I examined the effect of TRPV1, capsaicin receptor, on 
diet-induced obesity and insulin resistance in mice. TRPV1-deficient 
mice became more obese and get more fat accumulation on high-fat 
diet (HFD) feeding than wild-type (WT) mice. These results were 
caused by reduced locomotor activity in TRPV1 KO mice fed HFD for 
5 weeks. In TRPV1 KO mice, plasma leptin levels were decreased. 
 iii 
Although leptin up-regulates locomotor activity as well as energy 
expenditure, TRPV1 KO mice showed decreased activity and no 
changes in energy expenditure compared to WT mice, suggesting 
severe leptin resistance in TRPV1 KO mice fed HFD. All of these 
results indicated that TRPV1 is a regulator of energy balance and 
development of leptin resistance in obese mice. In addition, TRPV1 
deletion accelerates diet-induced insulin resistance. Insulin-stimulated 
glucose uptake in adipose tissues and heart was significantly 
diminished in HFD-fed TRPV1 KO mice. As one of the major causes 
of inflammation, oxidative stress and mitochondrial dysfunction, aging 
has been showed to induce obesity and insulin resistance. Deletion of 
TRPV1 in mice accelerated aging-induced weight gain and insulin 
resistance. Unlike the results fed HFD, aging promoted hepatic insulin 
resistance in TRPV1 KO mice compared to WT mice. Thus, these 
results provide new insight into the involvement of TRPV1 in 
development of obesity and insulin resistance and promising strategy 
against their pathogenesis. 
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Implications of capsaicin and its receptor, TRPV1 








The prevalence of obesity and a plethora of associated 
metabolic diseases to which it contributes is rapidly becoming a severe 
problem throughout the developed world. Recent evidence has shown 
that capsaicin, a pungent component of chilli peppers, and its receptor 
(transient receptor potential vanilloid type-1; TRPV1) exert significant 
effects on obesity and metabolic disorders. The administration of 
capsaicin has been found to prevent obesity and improve glucose 
homeostasis and insulin secretion in small rodents and humans. This 
review aims to summarize an overview of the obesity problem, as well 
as insulin/glucose metabolism and leptin/insulin resistance as 
contributors to obesity development and related metabolic disorders. I 
will also describe important effects of capsaicin and its receptor, 
TRPV1, in prevention of these diseases. Although the activation of 
TRPV1 by capsaicin improves metabolic disorders and prevents weight 
gain in small rodents and humans, its mechanistic role in obesity and 
metabolic disease prevention remains poorly understood. The objective 
is to provide new insights into the involvement of both capsaicin and 
 3 
TRPV1 in the development of obesity and metabolic disease, and 
potential strategies to attenuate pathogenesis. 
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1.1. Introduction  
While obesity in itself represents a serious disease, the 
condition can also markedly increase the likelihood of other common 
metabolic disorders including cardiovascular disease and diabetes (1). 
For those who suffer from obesity, the development of type 2 diabetes 
(T2D) is a common eventuality in many developed countries, of which 
many have an obesity problem of epidemic proportions. Although some 
studies have estimated that over 250 million people will be affected by 
T2D worldwide in the coming years, its primary causes and mechanism 
of development remain unknown (2). However, it has become clear that 
obesity-associated insulin resistance, a major characteristic of T2D, 
plays an important role in its development (3, 4). Since impaired insulin 
signaling associated with hyperinsulinemia is a critical feature of 
insulin resistance-induced T2D, the detection of insulin resistance itself 
is useful for the diagnosis of T2D. 
The medical definition of obesity is a condition in which a 
person has excess body fat mass. From fatty tissues, cytokines that 
regulate insulin/glucose metabolism are released, which act in positive 
or negative feedback loops to promote the development of insulin 
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resistance. High levels of several cytokines including interleukin (IL)-
1β, resistain, and TNF-α promote inflammatory responses, which can 
accelerate the onset of obesity and its related disorders (5, 6). In 
contrast, IL-10, an anti-inflammatory cytokine, as well as adiponectin 
and leptin can regulate catabolic metabolism to reduce adiposity (7, 8). 
In particular, leptin, as a master regulator of appetite and energy 
expenditure, plays a critical role in the hypothalamus to inhibit obesity 
and metabolic diseases. While obese animals and humans generally 
have higher levels of plasma leptin, its signaling is often impaired so 
that it cannot function normally. This failure to respond to the 
regulation of appetite and energy expenditure by leptin is referred to as 
leptin resistance. In this condition, rodents and human patients typically 
exhibit insulin resistance as well, supporting the idea that obesity, 
insulin resistance and leptin resistance develop through complex and 
inter-related mechanisms (9). 
Here, I review several lines of evidence that the capsaicin 
receptor, transient receptor potential vanilloid type-1 (TRPV1), 
represents a novel target for a new strategy to prevent obesity and its 
associated disorders. The receptor is widely expressed in adipose 
tissues, the pancreas, muscle and heart, which are major organs that 
 6 
regulate glucose/insulin metabolism. It also targets primary sensory 
neurons, suggesting that TRPV1 may be involved in the development 
of metabolic disorders (10, 11). This review will focus on the molecular 
mechanisms responsible for metabolic diseases, with a focus on obesity 
and T2D, summarizing evidence supporting the hypothesis that TRPV1 
plays an important role in their development. 
 
1.2. Development of metabolic diseases 
1.2.1. Obesity 
Obesity is a significant risk factor for the development of other 
diseases including diabetes, coronary heart disease, hypertension, 
atherosclerosis and certain forms of cancer. As a disease, it is defined 
by the WHO to entail a body mass index of over 30 kg/m2. Over 30% 
of the American population is considered obese, and 7-8% of Koreans 
have an obese phenotype. Obesity arises from excessive energy intake 
through food consumption and insufficient energy expenditure in order 
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to maintain cellular and organ function, physical activity and adaptive 
thermogenesis.  
Obesity is characterized as an excessive accumulation of fat, 
which increases the secretion of pro-inflammatory cytokines and 
chemokines including TNF- α and MCP-1 from adipose tissue, which 
acts to recruit macrophages that infiltrate into areas containing 
adipocytes (12). Infiltrated macrophages trigger a broad and chronic 
inflammatory response that strongly promotes obesity through a 
positive feedback mechanism. Obesity also develops through complex 
and chronic mechanisms involving several factors including genetics, 
as well as environmental factors such as culture, lifestyle and 
nutritional state (1). Although obesity and its related metabolic diseases 
are widespread and represent a growing challenge, the mechanistic 
understanding of their pathology and therapeutics remain unsatisfactory, 
underlining the critical need for further studies. 
 
1.2.2. Hyperglycemia, insulin resistance and type 2 diabetes 
Chronic adiposity resulting from excess food intake and 
insufficient energy expenditure can be thought of more simply as an 
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oversupply of energy in the body. A major energy source for the body 
is glucose; obese animals and human therefore frequently exhibit 
hyperglycemi,a which is a representative characteristic of diabetes 
mellitus and defined as having excessive plasma glucose (over 11.1 
mmol/L) (13). To reduce plasma glucose levels, β cells in the pancreas 
secret insulin to promote glucose uptake into organs such as muscle, 
adipose tissue, and the heart, while reducing glucose production in the 
liver (hepatic glucose production, HGP).  
Diabetes is defined as a condition involving abnormal glucose 
and insulin metabolism. There are two major types of diabetes; Type 1 
diabetes (T1D) is caused by genetic mutations that lead to defects in the 
immune system and destruction of insulin producing cells (islets). 
Patients diagnosed with T1D, therefore, exhibit impaired insulin 
secretion. In contrast, T2D is characterized by insulin resistance, and an 
attenuated or lack of response of the insulin receptor (IR) and its 
downstream signaling pathway to insulin stimulation even at high doses 
of insulin. Insulin resistance triggers an overload of the pancreas to 
compensate for the perceived lack of insulin, resulting in defects in the 
beta cells of the pancreas. In Korea, the number of patients diagnosed 
with type 2 diabetes was estimated at 7.08% of the total population in 
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2010 and has been expected to dramatically increase to over 10% by 
2030 (14). It is now known that obesity is a major cause of T2D with 
inflammation, mitochondrial dysfunction and endoplasmic reticulum 
(ER) stress (Fig. 1) involved, and statistical data shows that the 
incidence of T2D is strongly associated with obesity (1, 15). However, 
the specific mechanisms which lead from obesity to T2D are still 
unclear, requiring further studies into the molecular mechanisms 
involved in the development of T2D.  
 
1.2.3. Hyperlipidemia, hyperleptinemia and leptin resistance 
Abnormally elevated levels of body fat in obese animals and 
humans have been strongly implicated as a major factor in the 
development of hyperlipidemia and hyperleptinemia. Hyperlipidemia is 
a condition marked by greater than normal levels of plasma lipid or 
lipoproteins. It is a primary cause of metabolic disorders that are 
characterized by abnormal lipid metabolism including atherosclerosis, 
coronary heart disease, and cardiovascular disease (16). Abnormally 
elevated levels of free fatty acids (FFA) that accompany hyperlipidemia 




Figure 1. The causes of type 2 diabetes. Obesity induces chronic and 
systemic inflammation, oxidative stress, ER stress, and mitochondrial 
dysfunction. These are cellular events are strongly correlated to insulin 
resistance, which is characterized by impaired insulin signaling, and 
consequently promotes type 2 diabetes. 
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reduced glucose uptake in skeletal muscle, hepatic steatosis, increased 
secretion of pro-inflammatory cytokines, and consequently T2D 
[reviewed in (17)]. 
Adipocytes accumulate large numbers in obese animals and 
humans, and secrete high levels of pro-inflammatory cytokines. 
Examples include TNF-α, IL-1β, IL-6, and leptin. These signaling 
factors induce abnormal insulin action at high concentrations, whereas 
a lack of these cytokines can improve insulin sensitivity. This suggests 
that the overproduction of inflammatory cytokines in adipose tissue 
could play an important role in the development of insulin resistance. 
Leptin is a major hormone secreted from adipose tissue that regulates 
appetite and anabolic metabolic pathways as well as adaptive and 
innate immune responses (Fig. 2) (18, 19). Leptin was first 
characterized in 1950 in mutant obese mice that had deletions in the Ob 
gene that encodes leptin (20). The ob/ob mice, with point mutations in 
the leptin gene ob, or db/db mice, with homozygously deleted genes 
that encode the leptin receptor, are excessively obese, even when fed on 
chow diet. These mice also exhibit a decreased ability to control 
appetite, resulting in continuous food consumption. Leptin also acts on 




Figure 2. Regulatory mechanism of leptin feedback loop. Leptin 
produced from the ob gene in periphery cells including fatty tissues 
crosses the blood-brain barrier and activates the leptin receptor in 
hypothalamus. It triggers hypothalamic appetite suppression and 
elevated energy expenditure
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Leptin administration experiments in rodent and humans clearly 
supports the notion that leptin stimulates the brain to feel satisfied, 
triggering the cessation of food consumption [reviewed in (21)]. In 
addition, recent studies have demonstrated that leptin regulates energy 
expenditure and physical activity as well as appetite, suggesting 
another novel route for preventing the development of obesity and 
diabetes. Infusions or acute injections of leptin induce an increase in 
energy expenditure and locomotor activity (physical activity) in ob/ob 
mice that normally show extremely low levels of energy expenditure 
and movement (22, 23). 
Similar to conditions involving insulin resistance, obese animals 
and patients also exhibit leptin resistance. In the normal state, increased 
adipose tissue produces more leptin to lower food consumption and 
naturally regulate energy intake. Because obese animals and humans 
have dysregulated leptin signaling, they cannot recover from their 
abnormal state, exacerbating their obesity and diabetes. Recent clinical 
therapeutic studies to examine the positive effects of leptin for 
treatment of obesity and T2D have failed, possibly because obese 
patients with T2D have leptin resistance. However, the detailed 
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mechanisms responsible are not fully understood, strongly underlining 
the necessity of further studies for overcoming leptin resistance.  
 
1.3. Molecular mechanisms of TRPV1 and capsaicin in 
metabolic disease 
1.3.1. Capsaicin receptor: Transient receptor potential vanilloid 
type-1 
Capsaicin, a major pungent component found in chili pepper, 
specifically stimulates transient receptor potential vanilloid type-1 
(TRPV1), a non-selective cation channel. The consumption of 
capsaicin, which potently activates the TRPV1 channel, can arouse 
painful and thermogenic sensations that are commonly identified with 
as the spicy experience. The underlying importance of TRPV1 in 
neuroscience lies in its role as a major pain-sensing receptor, with its 
natural agonist, capsaicin, able to selectively react with TRPV1 and not 
with other TRP channels. There exist other agonists of TRPV1, for 
example, it can be activated by endovanilloid compounds, low pH 
(acidic condition) and high temperature (>43°C) (11). Since TRPV1 
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and capsaicin control thermogenesis, a crucial element in obesity and 
its related metabolic disorders, they could represent targets for novel 
therapeutic strategies to negate the onset of obesity and its associated 
metabolic disorders. 
 
1.3.2. In obesity: adipogenesis and thermogenesis 
Adipogenesis involves the production of fatty tissue through the 
conversion of preadipocytes to adipocytes via differentiation, and is the 
primary contributor to obesity. Several previous studies have reported 
clinical evidence that suggests the consumption of red peppers or 
capsaicin can decrease appetite, cause weight loss and stimulate 
thermogenesis via substrate oxidation from carbohydrate to the 
oxidation of fat (24-26). Epidemiological data also supports the notion 
that capsaicin consumption is related to a lower prevalence of obesity 
(27). Capsaicin treatment inhibits the differentiation of preadipocytes to 
adipocytes by regulating AMP-activated protein kinase (AMPK) and 
induces apoptosis and cell death in 3T3-L1 preadipocytes (28, 29). 
From the perspective of thermogenesis, capsaicin administration 
strongly increases whole-body energy expenditure, as well as brown 
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adipose tissue (BAT) temperature while increasing uncoupling protein 
1 (UCP1), a key molecule for the regulation of BAT-related in small 
rodents and humans (30-32). Contrary to these reports, however, 
several studies have reported failures in inducing increased energy 
expenditure and thermogenesis by capsaicin or foods containing 
capsaicin (33, 34). These inconsistent results could be caused by 
differences in sensitivity to capsaicin, which may be affected by 
variable levels of endogenous TRPV1 expression. The repeated 
exposure to capsaicin (chronic) or exposure to high doses of capsaicin 
(acute) induces degradation of the TRPV1 protein triggering a process 
known as “desensitization” (35, 36). Consistent with this idea, levels of 
TRPV1 expression are significantly reduced and responsiveness to 
capsaicin can then be impaired in obese rodents and humans (37).  
As a selective receptor of capsaicin, TRPV1 has been reported 
to be expressed in preadipocytes and visceral adipose tissue in both 
mice and humans (37), suggesting a possible role in the process of 
adipogenesis. Activation of TRPV1 in preadipocytes by capsaicin has 
been found to reduce adipogenesis by regulating peroxisome 
proliferator-activated receptor γ (PPARγ), CCAAT/enhancer-binding 
protein (C/EBPα), intracellular triglycerides, and glycerol-3-phosphate 
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dehydrogenase activity, while inducing apoptosis through the activation 
of caspase-3, Bas and Bak, cleavage of PARP, and decreased anti-
apoptotic Bcl-2 expression (28, 37, 38). High-fat diet-containing 
capsaicin also reduces body weight gain and accumulation of visceral 
and subcutaneous fatty tissue in mice. All of these results indicate that 
the activation of TRPV1 and the consumption of capsaicin are 
beneficial for potential therapeutic intervention to prevent obesity and 
its related disorders. 
In contrast, there have been contradictory reports using a 
TRPV1-null mouse model (39). TRPV1 knockout mice fed on a long 
term high-fat diet (HFD) for 25 weeks exhibited preventive effects 
against weight gain when compared to wild-type (WT) mice. This 
protective effect of TRPV1 deficiency against weight gain was found to 
be associated with a reduced accumulation of adipose tissue and 
hepatic steatosis by increased energy expenditure. These ambiguous 
results, strongly underline the need to reconsider the effects of TRPV1 




1.3.3. In diabetes mellitus: insulin secretion and insulin resistance 
Diabetes mellitus is categorized into 2 types. Type 1 diabetes 
(T1D) is caused by a lack of functional insulin secretion, while type 2 
diabetes (T2D) arises from impaired insulin signaling as a result of 
various environmental factors. Previous studies have reported that 
TRPV1 activation by capsaicin affects insulin secretion in animals and 
humans. Highly elevated expression of TRPV1 in the sensory nerve 
fibres that innervate the pancreas implies that TRPV1 could play an 
important role in insulin secretion (40-42). The administration of 
capsaicin in diabetic rats increases insulin secretion and insulin 
responses, and consequently improves glucose homeostasiss (41, 43). 
These results indicate that TRPV1 and its agonist, capsaicin are 
involved in insulin secretion by regulating sensory nerve fibres which 
affect the pancreas, suggesting that TRPV1 and capsaicin could be 
potentially useful in new strategies for the treatment of T1D. In non-
obese diabetic (NOD) mice, as a representative model for T1D, TRPV1 
is mutated to hypofunctional form, and capsaicin treatment in these 
mice prevents islet beta cells stress and inflammation (44). Since the in 
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vivo data in small rodent models remains controversial (45), further 
studies using TRPV1-null mice are required. 
 
1.5. Conclusions 
Over the past few decades, the role and mechanism of capsaicin 
and TRPV1 in metabolic diseases has increasingly been demonstrated. 
Although capsaicin can influence the pathogenesis of obesity and 
metabolic diseases positively, the roles of TRPV1, a capsaicin receptor, 
in these diseases and its mechanism of action have not been clearly 
elucidated. TRPV1, as a non-selective cation channel, primarily 
regulates the influx of calcium ions involved in the pathogenesis of 
various human diseases. Various evidences exist that suggests the 
possibility that TRPV1 plays a crucial role in the development of 
metabolic diseases. Thus, a clear understanding of the role of TRPV1 in 
metabolic disease will facilitate the development of new therapeutic 
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Obesity is a hallmark of many metabolic disorders and in recent 
decades has become a severe global health problem. Although a considerable 
amount of previous studies have supported the claim that calcium channels 
(including transient receptor potential (TRP) channels) are involved in the 
development of obesity, the mechanistic aspects are not fully understood. 
Among the TRP channels, transient receptor potential vanilloid type-1 
(TRPV1), a receptor for capsaicin (a pungent component of chilli peppers), 
has been reported to exhibit anti-obesity effects, although several studies have 
demostrated opposite results indicating pro-obesity effects for TRPV1-
deficiency models. These controversial results indicate the necessity for 
further studies of TRPV1 and its involvement in the development of obesity. 
Here, I demonstrate that TRPV1 deletion promotes the accumulation of fat 
mass and obesity resulting from lowered locomotor activity. Moreover, 
TRPV1 deficiency impairs leptin signaling by inducing leptin resistance in 
mice. These results suggest that the activation of TRPV1 by the natural 
agonist capsaicin may represent a promising new therapeutic agent for the 
treatment and prevention of obesity.  
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activity.
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2.1. Introduction  
Abnormally elevated levels of fat accumulation in obese animals and 
subjects strongly promotes the induction of macrophage infiltration into the 
fatty tissue, which providing a major impetus for the secretion of 
inflammatory cytokines and hormones such as interleukin (IL)-1b, IL-6, 
monocyte chemotactic protein-1 (MCP-1), tumor necrosis factor-alpha 
(TNFα), adiponectin, and leptin (1, 2). Among these signaling factors, leptin 
is a critical regulator of energy balance by inducing satiety and energy 
expenditure. It binds with the leptin receptor and activates downstream 
signaling pathways in the hypothalamus, which work to reduce appetite. 
According to previous studies, leptin also regulates locomotor activity (or 
physical activity), and voluntary movement independent from food-
anticipatory activity (3-5). In obese patients, leptin levels in the bloodstream 
are significantly lower, and leptin-replacement therapy can lead to weight loss 
(6, 7). Although there are many lines of evidence to support the notion that 
leptin remarkably improves obesity, associated hyperglycemia and insulin 
resistance in some animal models and humans (4, 8-12), several clinical leptin 
administration studies have failed to recover insulin resistance and weight 
gain in obese patients with type 2 diabetes (13-15). These ineffective leptin 
treatment studies may be the result of leptin resistance present in extremely 
obese or type 2 diabetic patients. 
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Leptin resistance is a representative characteristic of subjects with 
obesity and diabetes. Similar to insulin resistance, leptin resistance is define 
as a less or lack of response to leptin, even if administered with high doses of 
leptin. This outcome is a critical aspect for why leptin cannot be used as a 
therapeutic for the treatment of obesity and diabetes. Following a number of 
recent failures of leptin therapy due to leptin resistance, the demand for more 
insightful mechanistic studies to overcome leptin resistance has been growing. 
However, the underlying mechanisms and viable alternatives for the recovery 
of leptin resistance remain to be elucidated. In this study, I discovered that 
transient receptor potential (TRP) vanilloid type-1 (TRPV1) mediates the 
leptin signaling pathway, by demonstrating that a knockout of TRPV1 blocks 
leptin downstream pathway events such as STAT3 phosphorylation. This 
supports the idea that activation of TRPV1 by capsaicin or the other agonists 
might be a potential therapeutic strategy for the treatment of leptin resistance. 
The TRPV1 channel is a member of the TRP protein superfamily, a 
large group of cation-permeable channels expressed in mammalian cells. 
TRPV1 is a nonselective cation channel that is highly permeable to Ca2+ and 
Na2+, and is involved in thermogenesis and pain sensing (16-18). Capsaicin, a 
major component of chilli pepper, is a natural and specific agonist for the 
TRPV1 channel and induces the pain sensation and thermogenic reaction, 
colloquially known as the spicy sensation when eaten. Thermogenesis is a 
major component of energy expenditure and plays a crucial role in the energy 
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metabolism that regulates obesity (19). Therefore, chilli pepper and its major 
thermogenic component, capsaicin, could exhibit anti-obesity properties. A 
considerable number of previous studies have shown that chilli pepper or 
capsaicin-containing foods are associated with a reduced incidence of obesity, 
caused by reductions in heat generation and increases in energy expenditure 
(20-23). Epidemiological and clinical data shows that capsaicin consumption 
is correlated with a lower incidence of obesity in accordance with in vitro 
results indicating that capsaicin treatment reduces preadipocyte differentiation 
into mature adipocytes (20-22, 24-26). The activation of TRPV1 by capsaicin 
consumption has also been shown to significantly decrease the accumulation 
of body fat mass and body weight gain in mice (20). However, previous 
studies using a TRPV1 knockout mice model has revealed contradictory data 
indicating lower obesity and better thermogenic capacity in TRPV1 deficient 
mice compared to wild-type mice (27). Thus, I sought to determine the role of 
TRPV1 in high-fat diet (HFD)-induced obesity and energy imbalance using 
TRPV1-deficient mice. Here, I demonstrate that TRPV1 deletion aggravates 




2.2. Materials and Methods 
2.2.1. Animals 
TRPV1-deficient (TRPV1 KO) mice and WT littermates were 
purchased from Jackson Laboratory. For diet-induced obesity, mice were fed 
a high-fat diet (HFD) (55% fat by calories; Harlan Teklad TD93075) ad 
libitum for 5 or 9 weeks. The animal studies were approved by the 
Institutional Animal Care and Use Committee of the University 
Massachusetts Medical School. All studies at GSK were conducted after 
review by the GSK Institutional Animal Care and Use Committee and in 
accordance with the GSK Policy on the Care, Welfare, and Treatment of 
Laboratory Animals.  
2.2.2. Body composition and energy balance measurements 
Mice were housed under controlled temperature and lighting, with free 
access to food and water. Whole body fat and lean mass were noninvasively 
measured using 1H-MRS (Echo Medical Systems, Houston, TX). The 
food/water intake, energy expenditure, respiratory exchange ratio, and 
physical activity were assessed for 3 days using metabolic cages (TSE 
Systems, Chesterfield, MO). I used the TSE Systems LabMaster platform 
with easy-to-use calorimetry featuring fully-automated monitoring for food, 
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water and XYZ activity. LabMaster cages were used, that are similar to 
normal cages used for pets, thereby allowing the use of bedding in the cage 
and minimizing animal anxiety during the experimental period. The system 
provides intuitive software with flexibility for experimental setup and data 
utilization. 
2.2.3. Leptin/adiponectin measurement 
The plasma levels of leptin and adiponectin were measured using 
ELISA kits (ALPCO Diagnostics, Salem, New Hampshire, USA). To collect 
plasma samples, mice were fasted for 5 h in the morning. Using heparin-
treated capillary tubes, blood was collected carefully into heparin-treated 
eppen tubes, and centrifuged at 12,000 rpm for 3 mins in 4°C. For ELISA 
assays, the supernant of centrifuged blood was used, following the 
manufacturer’s instructions. 
2.2.4. Leptin infusion study 
To infuse leptin continuously (20 µg/day), osmotic pumps (1007D, 
Alzet Corp., Palo Alto, CA) were used as described in the manufacturer’s 
manual. Basal food intake was measured using metabolic cages for 3 days as 
described above. After survival surgery to insert the pumps, mice were housed 
in their original cages to recover from anesthesia and then placed in metablic 
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cages for 6 days to measure food intake during leptin infusion. To induce 
leptin resistance, mice were fed HFD for 9 weeks. The same procedures were 
then performed again. 
2.2.5. Leptin signaling in primary cultured mouse embryonic fibloblasts 
(MEFs) 
Primary cultured TRPV1 KO and WT MEFs were prepared from 
embryos at embryonic Day 13.5. The method for primary culture was 
modified from a previous study (28). Briefly, embryos were washed in DPBS 
and chopped with a blade and 23G needle. Embryos were trypsonized for 10 
mins at 37°C and were centrifuged at 1,000 rpm for 3 mins at 4°C. MEFs 
were cultured in Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 10% FBS, 100 units/ml penicillin, and 100 µg/ml 
streptomycin. TRPV1 KO and WT MEFs were treated with leptin (100 ng/ml) 
for 10 mins after serum deprivation for 18 h and then washed twice with cold 
DPBS and harvested. 
2.2.6. Leptin stimulation study  
To test leptin signaling in mice, mice were fasted overnight (~15 h) 
and injected with leptin intraperitoneally. After 2 h, mice were anesthestized 
with intraperitoneal ketamine (100 mg/ml) and xylazine (20 mg/ml) mixture. 
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The hypothalamus was taken from each mouse within 5 mins. After lysis of 
tissue samples, a total of 50 µg of protein was used for Western blotting.   
2.2.7. Western blotting  
Total cell and tissue lysates from mice were prepared and subjected to 
Western blot as described previously (29). After cell lysis, the protein 
concentration was determined using a dye-binding protein assay kit (Bio-Rad 
Laboratories, Hercules, CA) as described in the manufacturer’s manual. 
Protein lysate (50 µg) was subjected to 10% SDS PAGE and 
electrophoretically transferred to a nitrocellulose membrane (Amersham 
Pharmacia Biotech). After blotting, the membrane was incubated with the p-
STAT3 (Tyr705), STAT3, and β-actin primary antibodies at 4ºC overnight. 
Protein bands were visualized using a chemiluminescence detection kit after 
hybridization with a horseradish peroxidase-conjugated secondary antibody.  
For the in vivo Western blots, the hypothalamus was removed from 
each mouse, and extracted with T-PER tissue protein extraction reagent 
(Pierce, Rockford, IL) containing 1% phosphatase inhibitor cocktail 2 (Sigma 
Chemical, St. Louis, MO) and the protease inhibitor phenylmethylsulfonyl 
fluoride (Calbiochem, La Jolla, CA) to isolate the proteins. The samples were 
then homogenized using ultra turrax homogenizer (Next Advance Inc.). The 
lysates were centrifuged at 14,000 rpm for 15 min, and the protein 
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concentration was determined using a protein assay kit (Bio-Rad 
Laboratories). Tissue lysates were subjected to 10% SDS-PAGE and 
transferred to a nitrocellulose membrane (Amersham Pharmacia Biotech, 
Buckhinghamshire, UK). Membranes were processed and proteins analyzed 
as for the in vitro Western blot assay. 
 
2.2.8. Statistical analysis  
Data are expressed as mean ± S.E. values, and ANOVA was used for 
multiple statistical comparisons. A probability value of p<0.05 was used as 
the criterion for statistical significance. All analyses were performed using 




2.3.1. Deletion of TRPV1 induces higher accumulation of fat and obesity 
during HFD feeding 
To determine the effect of TRPV1 on HFD-induced obesity, TRPV1 
knockout (KO) mice and wild-type (WT) littermates were fed HFD (55% fat 
by calories) ad libitum for 5 weeks and body composition was measured 
weekly. Body composition data showed that the body weight of TRPV1 KO 
mice was significantly higher than WT after 5 weeks of HFD (Figure 1A), but 
the lean mass of each group was not statistically different (Figure 1C). 
Additionally, TRPV1 KO mice had remarkably more fat mass than WT mice 
after HFD feeding, whereas there was no difference in the body weight of 
both TRPV1 and WT mice fed chow diet (Figure 1B). Unlike previous studies 
using TRPV1 KO mice fed 11% fat diet(27), TRPV1 KO mice were more 
obese, resulting from higher fat mass than WT mice on HFD feeding. This 
finding coincides with some previous reports demonstrating that TRPV1 
activation by capsaicin consumption improves the prevention of obesity and 
fat accumulation (20).  
 




Figure 1. Effect of TRPV1 deletion on HFD-induced weight gain. (A) Body weight 
was measured during 5 weeks of HFD (n=10-12, *p<0.05 vs. WT mice fed HFD). (B 
and C) Whole body fat (B) and lean mass (C) were measured weekly using 1H-MRS 
during the experiment. WT, wild type C57BL/6J mice; KO, TRPV1 KO mice. 
*p<0.05
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Since TRPV1 KO mice fed HFD were more obese than WT mice fed HFD, 
we next examined the effect of TRPV1 deletion on energy balance using 
metabolic cages and TRPV1 KO and WT mice fed on a chow diet and after 4 
weeks of HFD feeding. Food intake (Figure 2A), VO2 consumption and VCO2 
production (Figure 2B), and energy expenditure (Figure 2C) normalized to 
whole body lean mass (measured using 1H-MRS) were not different between  
TRPV1 KO mice and WT mice on both fed chow diet and HFD. However, the 
TRPV1 deficiency caused a selective change in physical activity (35% of 
reduction) in TRPV1 KO mice during the night from 6pm to 6am for 3 days 
(Figure 2D and E), suggesting that TRPV1 deletion induces lower physical 
activity in mice.  
 
2.3.3. Deletion of TRPV1 induces increased plasma leptin levels 
compared to WT mice after HFD  
Since physical activity was decreased in TRPV1 KO mice, I sought to 
determine which factors were involved. Previous studies have suggested that 
leptin controls locomotor activity and energy expenditure as well as food 
intake (3, 5). The plasma leptin levels of TRPV1 KO mice were higher than in 
WT mice fed on both chow and HFD (Figure 3A). To confirm that the 




Figure 2. Reduced physical activity in TRPV1-deficient mice. Indirect 
calorimetry was performed using metabolic cages in male WT (n=6) and 
TRPV1 KO mice (n=6) before and after HFD feeding. (A) Daily food intake 
in WT and TRPV1 KO mice. All data are expressed per kg of whole body 
lean mass measured using 1H-MRS. (B) Average VO2 consumption (upper) 
and VCO2 production (bottom) in each mouse. (C) Average energy 
expenditure rates. (D) 24-h physical activity in HFD-fed mice. (E) Total beam 
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break counts, used as a measure of physical activity during nighttime. 
*p<0.05, p value denotes the statistical significance vs. WT mice fed HFD. 
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by higher fat mass, I normalized plasma leptin levels to fat mass for all mice 
(Figure 3B). Normalized leptin level in TRPV1 KO mice was also 
significantly higher than in WT mice. In addition, levels of the alternate 
adipokine secreted from fat tissues, adiponectin, were measured to confirm 
which leptin level was elevaed by increased fat mass in TRPV1-deficient 
mice (Figure 3C). Unlike leptin levels, plasma adiponectin levels of TRPV1 
KO mice were not statistically different from levels in WT mice. TRPV1-
deficient mice therefore had higher plasma leptin levels, suggesting that 
TRPV1 is involved in leptin secretion or related signaling pathways. 
 
2.3.4. Negative correlation between leptin and physical activity/energy 
expenditure in TRPV1 KO mice fed HFD  
Although TRPV1 KO mice had greater plasma leptin levels, their food intake 
and energy expenditure remained unchanged compared to WT mice after 5 
weeks of HFD feeding (Figure 2A and C), and even physical activity during 
night time was significantly decreased in TRPV1 KO mice (Figure 2 D and E). 
Figure 4 reveals the opposite trends for physical activity and energy 
expenditure vs. plasma leptin levels for each mouse. WT mice had relatively 
positive correlations for physical activity (Pearson R = 0.939, p value=0.061) 
and energy expenditure (Pearson R = 0.847, p value=0.15) vs. concentrations  
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Figure 3. TRPV1 deficient mice have higher levels of leptin. (A) Plasma 
leptin levels were measured by ELISA assay according to the manufacturer’s 
instructions in WT (n=12) and TRPV1 KO (n=10) mice before and after HFD 
feeding for 5 weeks. (B) Plasma leptin levels were normalized to whole body 
fat mass measured using 1H-MRS. (C) Plasma high molecular weight (HMW) 
proteins and total adiponectin were measured using an ELISA kit. Average % 
of HMW adiponectin per total adiponectin is represented. *p<0.05
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of leptin levels normalized to fat mass, whereas TRPV1 KO mice showed 
negative correlations (Pearson R = -0.929, p value = 0.022 for physical 
activity and Pearson R = -0.984, p value = 0.015 for energy expenditure) with 
statistical significance. All of these data indicate that there was impaired 
leptin sensitivity in TRPV1 KO mice fed HFD even with higher fat mass and 
plasma leptin levels, suggesting the existence of leptin resistance. 
 
2.3.5. TRPV1 channel impairment promotes leptin resistance in mice fed 
HFD 
To examine the effect of TRPV1 deletion on leptin resistance in mice, I 
performed leptin infusion study using an osmotic pump. To match the average 
plasma leptin levels of WT and TRPV1 KO mice fed HFD for 5 weeks (~10 
ng/ml), leptin was infused at a concentration of 20 µg/day, for both groups of 
mice fed chow diet. After 6 days, the average plasma leptin levels in WT and 
TRPV1 KO mice were not significantly different (Figure 5A-b). Under leptin 
infusion conditions, food intake for WT mice was remarkably reduced by 
leptin stimulation at Day 1, this tendency remained until Day 6 (Figure 5A-a). 
However, in TRPV1 KO mice, reductions in food intake was less than for WT 




Figure 4. Correlation analysis between normalized leptin levels and physical 
activity or energy expenditure in HFD-fed TRPV1 KO. Plasma leptin levels were 
normalized to whole body fat mass measure using 1H-MRS in each mouse. Energy 
expenditure is expressed per kg of whole body lean mass measured using 1H-MRS. 
Correlation between physical activity (A) or energy expenditure (B) and normalized 
leptin levels were based on average values collected over 72 h. Each dot represents 
normalized plasma leptin vs. physical activity (A) or energy expenditure (B) in WT (n 
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= 4, a) and TRPV1 KO (n = 4-5, b) mice fed HFD. Pearson R value and p value for 
correlation coefficients of physical activity (A-c) or energy expenditure (B-c) vs. 
normalized leptin levels are shown.
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To induce leptin resistance in both WT and TRPV1 KO mice, mice were fed 
HFD for 9 weeks. A leptin infusion study was then performed again in WT 
and TRPV1 KO mice (Figure 5B-a). I observed that after 9 weeks of HFD 
feeding, TRPV1 and WT mice exhibited leptin resistance at Day 6 with no 
changes in food intake. At Day 1, however, TRPV1 did not respond to leptin 
infusion, whereas WT mice on less food intake still responded to high doses 
of leptin. All of these results indicate that TRPV1 KO mice exhibited severe 
leptin resistance compared to WT mice. Consistent with these results from the 
leptin infusion study with TRPV1 KO mice, capsaicin oral administration for 
12 weeks with HFD decreased food intake (Figure 6A), whereas plasma leptin 
levels were not altered in TRPV1 KO mice compared to WT mice (Figure 6B). 
Thus, these results suggest that the deletion of TRPV1 induces leptin 
resistance, and the activation of TRPV1 by capsaicin improves leptin 
sensitivity. 
2.3.6. Deletion of TRPV1 attenuates leptin signaling in MEFs and mice  
Leptin signaling was examined using Western blot in TRPV1 KO 
MEFs and WT MEFs. Leptin-stimulated phosphorylation of STAT3 at 
Tyr705 was elevated by ~3-fold in WT MEFs, but total STAT3 expression 
remained unchanged after leptin treatment (Figure 7A). However, basal levels 





Figure 5. TRPV1-deficient mice are more leptin resistant compared to WT mice. 
A leptin infusion study was performed to test leptin resistance in WT (n=4) and 
TRPV1 KO mice (n=5) fed on chow diet and HFD for 9 weeks. After recovering from 
surgery for insertion of osmotic pumps, mice were acclimatized to metabolic cages 
for 24 h. Food intake was measured using the metabolic cage; basal levels in each 
mouse were obtained by measuring average food intake for 3 days. Food intake (a) 
and plasma leptin levels (b) of WT and TRPV1 KO mice fed chow diet (A) and HFD 




Figure 6. The inhibitory effect of capsaicin on energy intake during HFD feeding. 
(A) Daily food intake was measured using metabolic cages for vehicle- and capsaicin-
treated mice at the beginning and end of each experiment. (B) Plasma leptin levels in 
mice orally injected with vehicle and capsaicin were detected by ELISA. *p<0.05
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MEFs in the absence of leptin stimulation compared to WT MEFS. In 
addition, TRPV1 KO MEFs did not respond to leptin stimulation, suggesting 
the existence of impaired leptin signaling in TRPV1 KO MEFs. To confirm 
the inhibitory effect of TRPV1 deletion on leptin-induced phosphorylation of 
STAT3, we injected leptin (2mg/kg body weight) intraperitoneally into WT 
and TRPV1 KO mice. After 2 h, phosphorylation of STAT3 at Tyr705 in the 
hypothalamus was increased in both WT and TRPV1 KO mice, but the 
increased levels of p-STAT3 in TRPV1 KO mice were reduced compared to 
levels in WT mice (Figure 7B). All of these results indicate that leptin 




Figure 7. Phoshorylation of STAT3 at Tyr705 stimulated by leptin is reduced in 
TRPV1-deficient MEFs and mice. (A) Primary cultured MEFs from WT and 
TRPV1 KO embryos were seeded in 100 mm dishes and serum-deprived for ~18 h. 
After 10 mins treatment with leptin (100 ng/ml) or vehicle control, cells were 
harvested. Levels of protein phosphorylation and expression in lysates from WT and 
TRPV1 KO MEFs were determined by Western blot using specific antibodies against 
p-STAT3 (Tyr705), STAT3, and β-actin. (B) Phosphorylation of STAT3 at Tyr705 
was examined in the hypothalamus of WT and TRPV1 KO mice intraperitoneally 
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Previous evidence implicates dietary calcium consumption in the 
modulation of adipocyte metabolism and obesity (30-33), and recent studies 
have shown that calcium channel blockers attenuate obesity and related 
hypertension, suggesting that calcium channels are directly involved in energy 
metabolism and the development of metabolic syndromes (34, 35). Recently, 
TRP channels, as mediators of cation influx (including Ca2+) induced by 
phycial and chemical stimuli, have been examined for their roles in metabolic 
diseases such as obesity, diabetes, hypertension, cardiovascular disease, and 
kidney disease [reviewed in (36, 37)]. In obesity studies, expression of 
TRPC4, TRPM8, TRPP2, TRPML, and TRPV6 were reported to correlate 
with obesity in genome scans (38). TRPM5 is a major component of taste 
sensory signaling and is highly expressed in the gastric mucosa of obese 
subjects, where it regulates energy consumption (39, 40). TRPV4 has been 
recently reported to control energy homeostasis and promote obesity (41, 42). 
However, the role of TRPV1 in obesity is controversial and considerable 
numbers of previous studies have reported anti-obesity effects due to TRPV1 
activation (20, 21), while TRPV1-null mice are resistant to diet-induced 
obesity (27). In the present study, I demonstrated that TRPV1 deletion 
promotes HFD-induced obesity and leptin resistance by down-regulating 
leptin signaling. Even higher levels of plasma leptin were present in TRPV1-
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deficient mice than WT mice, and leptin sensitivity of TRPV1 KO mice were 
remarkably attenuated through decreased locomotor activity.  
Since leptin resistance is a primary cause for the failure of leptin 
therapy in recent obese patient studies, new strategies to overcome this 
condition are needed (14, 15). However, a detailed mechanistic understanding 
of the development and progression of leptin resistance is urgently needed. 
TRPV1-null mice have higher levels of plasma leptin than WT mice with 
impaired leptin signaling, which subsequently promotes leptin resistance, 
suggesting a new role for TRPV1 and its agonists as components of a novel 
strategy to address leptin resistance. Nevertheless, further studies into how 
TRPV1 regulates leptin signaling pathways are needed to elucidate the 
pathways responsible. 
In the present study, I have shown that TRPV1 regulates energy 
balance, and its deletion promotes diet-induced obesity in mice. This 
detrimental effect of TRPV1 deficiency on obesity results from loss of 
sensitivity to leptin-controlled energy homeostasis. In this regard, the 
activation of TRPV1 by its agonists, such as capsaicin, may provide a solution 
for the maintenance of metabolic state and represent a novel therapeutic target 
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Obesity-induced insulin resistance is a representative 
characteristic of type 2 diabetes (T2D). Impaired insulin signaling in 
insulin resistant states can destroy glucose homeostasis, causing various 
metabolic diseases such as hypertension, atherosclerosis and coronary 
disease. Although there have been reports that the activation of TRPV1 
by capsaicin improves insulin sensitivity, the physiological role of 
TRPV1 is still unclear. In the current study, we used a 
hyperinsulinemic-euglycemic clamp assay to examine insulin 
sensitivity in live mice and found that TRPV1 deletion increased high-
fat diet (HFD)-induced fat accumulation and whole body insulin 
resistance. The whole body insulin resistance observed in TRPV1-
deficient mice fed with HFD was caused by impaired insulin sensitivity 
in insulin-responsive tissues including white adipose tissue, brown 
adipose tissue, and the heart. This study identifies a novel role for 
TRPV1 in the regulation of insulin resistance.  
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3.1. Introduction  
Obesity, a hallmark of metabolic syndrome, is a major risk 
factor for the development of diabetes, hypertension and dyslipidemia. 
Obesity-associated insulin resistance strongly induces type 2 diabetes 
(T2D), which is a representative characteristic of T2D (1). Insulin 
resistance is commonly induced by mitochondrial dysfunction, 
endoplasmic recticulum (ER) stress, oxidative stress, and obesity-
related inflammation (2-5). Insulin resistance is a condition in which 
cells fail to respond to insulin to reduce blood glucose levels, due to 
impaired insulin receptor (IR) activation. Inadequate responses to 
insulin signaling leads to an overproduction of insulin from the beta 
cells of the pancreas, which eventually damages them (6). To prevent 
T2D, controlling insulin resistance is a key strategy.  
  Insulin acts on multiple tissues including the pancreas, liver, 
muscle, adipose tissues and heart, to lower whole-body plasma glucose 
levels by stimulating glucose uptake. When blood glucose levels are 
high, beta cells in the pancreas generate high levels of insulin. Secreted 
insulin circulates through the body in the bloodstream to reduce 
glucose levels. Insulin stimulation in the liver ceases hepatic glucose 
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production to inhibit catabolism. In other insulin-responsive tissues 
such as the muscle, adipose tissues and heart, glucose is translocated 
and converted to glycogen or pyruvate and fat is stored as triglyceride 
(TG). Thus, sensitive responses to insulin are a crucial mechanism for 
maintaining energy homeostasis. 
 The development of insulin resistance is a complicated process 
with various signaling pathways involved. In normal conditions, insulin 
induces phosphorylation of the insulin receptor (IR), a tyrosine kinase, 
and phosphorylated IR in turn activates downstream effector molecules 
including insulin receptor substrate 1 and Akt, which promote 
translocation of GLUT4-containing storage vesicles to the plasma 
membrane to allow the entry of glucose into the cell. Translocated 
glucose into muscle cells is converted to glycogen or pyruvate through 
glycolysis. Insulin stimulates the liver to synthesize glycogen or TG. In 
adipose tissue, insulin increases TG levels and decreases lipolysis to 
reduce the production of fatty acids (FA). In insulin-resistant conditions, 
insulin-mediated glucose uptake in muscle, adipose tissue, and other 
tissues including the brain and heart is impaired. As a result, excess 
glucose is diverted to the liver, causing accumulation of liver lipids and 
impairment in controlling gluconeogenesis and glycogen synthesis. In 
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addition, insulin resistance in adipose tissue promotes re-esterification 
of lipids (FA) and further exacerbates insulin resistance by increasing 
lipolysis (7). 
Transient receptor potential vanilloid subfamily type-1 
(TRPV1) has been reported to be associated with obesity and insulin 
resistance. Previous studies have shown that chilli pepper or capsaicin-
containing foods improve glucose homeostasis and insulin sensitivity 
(8, 9). However, the physiological role of TRPV1 in the development 
of insulin resistance remains poorly understood.  
In the previous chapter, we demonstrated that TRPV1 deficient 
mice became more obese and accumulated more fat compared to wild-
type (WT) mice in a high-fat diet (HFD) model. In addition, deletion of 
TRPV1 induced severe leptin resistance, which is consistent a result 
with prior capsaicin gavage data showing lowered food intake. Here, 
we examined the effect of TRPV1 deletion on HFD-induced insulin 
resistance to further investigate the function of TRPV1 in obesity and 
associated metabolic disorders. We found that loss of TRPV1 
aggravated HFD-induced insulin resistance, which resulted from 
defects in insulin action in white adipose tissue (WAT), brown adipose 
tissue (BAT) and heart, but not in skeletal muscle and liver.   
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3.2. Materials and Methods 
3.2.1. Animals and reagents 
TRPV1-deficient (TRPV1 KO) mice (n = 10) and WT 
littermates (n = 12) were purchased from Jackson Laboratory. For the 
diet-induced obesity study, 11- to 14-week-old mice were fed a HFD 
(55% fat by calories; Harlan Teklad TD93075) ad libitum for 5 weeks. 
The animal studies were approved by the Institutional Animal Care and 
Use Committee of the University of Massachusetts Medical School.  
3.2.2. Body composition  
Mice were housed under controlled temperature and lighting, 
with free access to food and water. Whole body fat and lean mass were 
noninvasively measured using 1H-MRS (Echo Medical Systems, 
Houston, TX).  
3.2.3. Hyperinsulinemic-euglycemic clamp 
Following chow or HFD, a survival surgery was performed at 4 
–5 days before clamp experiments to establish an indwelling catheter in 
the jugular vein. On the day of the experiment, mice were fasted 
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overnight (~15 h), and a 2-h hyperinsulinemic euglycemic clamp was 
applied in conscious mice with a primed and continuous infusion of 
human insulin (150 mU/kg body wt priming followed by 2.5 mU·kg-1 
·min-1, Humulin; Eli Lilly). To maintain euglycemia, 20% glucose was 
infused at variable rates during clamps. Whole body glucose turnover 
was assessed with a continuous infusion of [3-3H]glucose, and 2-
deoxy-D-[1-14C]glucose (PerkinElmer) was administered as a bolus (10 
µCi) at 75 min after the start of the clamping to measure insulin-
stimulated glucose uptake in individual organs. At the end of the 
clamping, mice were anesthetized, and tissues were extracted for 
biochemical analysis (10). 
3.2.4. Biochemical analysis and calculation 
The glucose concentration during the clamping was analyzed 
using 10 µl of plasma with a glucose oxidase method and a Beckman 
Glucose Analyzer 2 (Beckman, Fullerton, CA). Plasma concentrations 
of [3-3H]glucose, 2-deoxy-D-[1-14C]glucose, and 3H2O were 
determined after deproteinization of plasma samples as previously 
described (11). For the determination of tissue 2-deoxy-D-[1-
14C]glucose-6-phosphate content, tissue samples were homogenized, 
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and the supernatants were subjected to an ion-exchange column to 
separate 2-deoxy-D-[1-14C]glucose-6-phosphate from 2-deoxy-D-[1-
14C]glucose. 
Rates of basal and insulin-stimulated whole-body glucose 
turnover were determined as the ratio of the [3H]glucose infusion rate 
(disintegrations per minute [dpm]) to the specific activity of plasma 
glucose (dpm/µmol) at the end of the basal period and during the final 
30 min of the clamping, respectively. Hepatic glucose production 
(HGP) during the clamping was determined by subtracting the steady-
state glucose infusion rate from the whole-body glucose turnover rate. 
Whole-body glycolysis and glycogen/lipid synthesis were calculated as 
previously described (11).  
3.2.5. Plasma insulin measurement 
The plasma levels of insulin were measured using ELISA kits 
(ALPCO Diagnostics, Salem, New Hampshire, USA). Plasma samples 
used for insulin ELISA were obtained from mice at the beginning and 
end of the hyperinsulinemic-euglycemic clamp. Using heparin-treated 
capillary tubes, blood was collected carefully into the heparin-treated 
eppen tube, and centrifuged at 10,000 rpm for 1 min. For the ELISA 
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assay, the supernatant of centrifuged blood was used following the 
manufacturer’s instruction. 
3.2.6. Glucose uptake assay  
At the end of hyperinsulinemic-euglycemic clamping, 
gastrocnemius muscle, WAT, BAT, and heart were extracted from 
anesthetized mice. Glucose uptake in individual tissues was calculated 
from the plasma 2-deoxy-D-[1-14C]glucose profile, which was fitted 
with a double exponential or linear curve using MLAB (Civilized 
Software, Bethesda, MD) and tissue 2-deoxy-D-[1-14C]glucose-6-
phosphate content. 
2.2.7. Western blotting  
WAT and heart tissue lysates were prepared from anesthetized 
mice at the end of the experiment and subjected to Western Blot. 
Tissues were extracted with T-PER tissue protein extraction reagent 
(Pierce, Rockford, IL) containing 1% phosphatase inhibitor cocktail 2 
(Sigma Chemical, St. Louis, MO) and the protease inhibitor 
phenylmethylsulfonyl fluoride (Calbiochem, La Jolla, CA). The 
samples were then homogenized and centrifuged at 14,000 rpm for 15 
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min at 4°C. Tissue lysates (50 µg) were subjected to 10% SDS-PAGE 
and transferred to a PVDF membrane (Biorad Laboratories Inc.). After 
blotting, the membrane was incubated with p-Akt (Ser473), Akt, p-
STAT3 (Tyr705), STAT3, or GAPDH primary antibodies at 4ºC 
overnight. Protein bands were visualized by a chemiluminescence 
detection kit after hybridization with a horseradish peroxidase-
conjugated secondary antibody.  
3.2.8. Statistical analysis  
Data are expressed as mean ± S.E. values, and ANOVA was 
used for multiple statistical comparisons. A probability value of p<0.05 
was used as the criterion for statistical significance. All analyses were 




3.3.1. HFD-induced obesity and insulin resistance are increased in 
TRPV1 knockout mice 
To determine the effect of TRPV1 on HFD-induced obesity, TRPV1 
knockout (KO) mice and wild-type (WT) littermates were fed a HFD 
(55% fat by calories) ad libitum for 5 weeks and were measured for 
body composition at the beginning and end of the experiment. Whole 
body fat mass was significantly increased in TRPV1 KO mice 
compared to WT littermates after 5 weeks of HFD feeding (Figure 1). 
To further investigate the effect of TRPV1 deletion on HFD-induced 
insulin resistance, we performed a hyperinsulinemic-euglycemic clamp 
using WT and TRPV1 KO mice. It clearly exhibited defects in insulin 
sensitivity after 5 weeks of HFD feeding compared to chow diet 
feeding in WT mice (Figure 2A). Moreover, the glucose infusion rate 
of TRPV1 KO mice on HFD was significantly lower than that of WT 
mice on HFD (p = 0.038 vs. WT mice fed HFD). The whole body 
glucose turnover rate was reduced in TRPV1 KO mice after 5 weeks of 





Figure 1. TRPV-deficient mice become more obese than WT mice fed a HFD. 
Whole body fat mass was measured using 1H-MRS at the beginning and end of the 
experiment. WT, wild type C57BL/6J mice. KO, TRPV1 KO mice. *p<0.05
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glycolysis of HFD-fed TRPV1 KO mice was slightly reduced 
compared to HFD-fed WT mice, but there was no statistical 
significance (p = 0.069, Figure 2C). There was no difference in plasma 
insulin level between WT and TRPV1 KO group (Figure 2D), and this 
result demonstrates that insulin resistance in TRPV1 KO mice is not 
caused by differences in the amount of whole body insulin. Collectively, 
these results indicate that TRPV1 deletion reduces whole body insulin 
sensitivity compared to WT mice after HFD feeding for 5 weeks. 
  
3.3.2. Deletion of TRPV1 does not affect insulin action in liver and 
skeletal muscle  
Since HFD-fed TRPV1 KO mice showed increased whole body insulin 
resistance compared to HFD-fed WT mice, we examined the effect of 
TRPV1 deletion on insulin action in insulin-responsive tissues. The 
liver is a representative organ that responds to insulin to reduce glucose 
production. There was no difference in basal levels of hepatic glucose 
production (HGP) between WT and TRPV1 KO mice in either chow 
diet or HFD groups (Figure 3A). After high doses of insulin stimulation 




Figure 2. Deletion of TRPV1 promotes HFD-induced whole body insulin 
resistance in mice. (A) Steady-state glucose infusion rate during hyperinsulinemic-
euglycemic clamping in conscious mice. (B) Insulin-stimulated whole-body glucose 
turnover was calculated using [3H]glucose infusion during clamping. (C) Insulin-
stimulated whole body glycolysis was estimated during clamping. (D) Plasma insulin 
levels were measured by ELISA. Plasma samples were taken from mice at the 
beginning and end of clamping. *p<0.05 
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both WT and TRPV1 KO mice (Figure 3B). Hepatic insulin action 
calculated using clamp/basal HGP was markedly reduced by HFD in 
WT mice (Figure 3C). However, the difference of insulin action in the 
liver between HFD-fed WT and HFD-fed TRPV1 KO mice was not 
detectable, suggesting that deletion of TRPV1 does not affect hepatic 
insulin action. 
Skeletal muscle, which is another insuling-responsive tissue, 
was used to measure insulin action (Figure 3D). Muscle glucose uptake 
rates were not changed by TRPV1 deletion. These results suggest that 
TRPV1 is not involved in insulin action in the liver or the skeletal 
muscle.  
3.3.3. Deletion of TRPV1 reduces glucose uptake into adipose 
tissues and heart  
To further investigate which organ is involved in whole-body 
insulin resistance in TRPV1-deficient mice, we performed a glucose 
uptake assay using WAT, BAT, and heart tissue. In adipose tissue, 





Figure 3. Deletion of TRPV1 does not affect HFD-induced insulin resistance in 
liver and skeletal muscle. (A, B, and C) Hepatic glucose production was estimated 
using [3H]glucose during clamping. Using basal HGP (A) and clamp HGP (B), hepatic 
insulin action (C) was calculated. (D) Insulin-stimulated glucose uptake in skeletal 
muscle. *p<0.05 
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hyperinsulinemic-euglycemic clamping, glucose uptake was similarly 
accelerated in both WT and TRPV1 fed on chow diet (Figure 4A). 
After HFD feeding for 5 weeks, glucose uptake levels in adipose 
tissues including white and BAT tissues were significantly reduced in 
WT mice compared to chow diet-fed WT mice (Figure 4A and B). 
HFD-fed TRPV1 KO mice exhibited a stronger reduction in glucose 
uptake compared to that of HFD-fed WT mice in WAT (41% 
reduction) and BAT tissue (35% reduction). In addition, glucose uptake 
in the heart, a major organ participating in the uptake and use of 
glucose from fat sources, was decreased by 29% in HFD-fed TRPV1 
KO mice compared to HFD-fed WT mice. Therefore, we have 
concluded that TRPV1 deletion induces impaired insulin sensitivity in 
adipose tissues and the heart, leading to whole-body insulin resistance 
during HFD feeding in mice. 
3.3.4. TRPV1 deficiency induces impaired insulin signaling in WAT 
after HFD feeding in mice 
Since, HFD-fed TRPV1 KO mice exhibited insulin resistance in 




Figure 4. TRPV1-deficient mice become insulin resistant in adipose tissues and 
heart during HFD feeding. Insulin-stimulated glucose uptake in WAT (A), BAT (B), 
and heart (C) were measured using tissue 2-deoxy-D-[1-14C]glucose-6-phosphate 
content during clamping. *p<0.05 
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deletion on HFD-induced insulin signaling pathways in WAT (Figure 
5A).  
Although the WAT of TRPV1 KO mice was more insulin 
resistant than that of WT mice, phosphorylation of Akt at Ser 473 was 
not altered in TRPV1 KO mice fed HFD. However, STAT3 
phosphorylation levels stimulated by insulin during hyperinsulinemic-
euglycemic clamping were significantly reduced in WAT taken from 
HFD-fed TRVP1 KO mice (Figures 5A and B). In the heart, 
phosphorylation of Akt was significantly reduced in both WT and 
TRPV1 KO mice after 5 weeks of HFD (Figure 6). However, we did 
not find any differences in phosphorylation levels of Akt and STAT3 
between WT and TRPV1 KO mice. Thus, deletion of TRPV1 




Figure 5. The effect of TRPV1 deletion on insulin-stimulated phosphorylation of 
Akt and STAT3 in WAT. (A) Insulin-stimulated phosphorylation of Akt and STAT3 
levels were evaluated by Western blot. WAT were taken from WT and TRPV1 KO 
mice at the end of hyperinsulinemic-euglycemic clamping. (B) Quantitative analysis 




Figure 6. The effect of TRPV1 deficiency on phosphorylation of Akt and STAT3 
induced by insulin in heart tissue. Heart tissues taken from WT and TRPV1 KO 




Insulin resistance is a representative characteristic of T2D and 
plays a major role in beta cell defects and the development of various 
metabolic syndromes. Insulin resistance is commonly identified in 
obese people, suggests its close association with obesity and T2D. 
Previous studies have reported the attenuation of IR-IRS-Akt and 
STAT3 signaling pathways as a mechanism for the development of 
insulin resistance. Although several strategies were suggested to 
overcome insulin resistance, the successful development of new agents 
to prevent and treat insulin resistance in obese or T2D patients is 
needed. 
The majority of previous reports regarding TRPV1 and diabetes 
have focused on its effect on insulin secretion. TRPV1 channels in islet 
beta cells are involved in insulin secretion (12) and TRPV1+ fibers are 
associated with insulin release and energy expenditure (13-15). TRPV1 
also innervates various tissues including pancreas and adipose tissues 
and regulates insulin response (13, 14, 16, 17). However, the role of 
TRPV1 in vivo is still controversial. A previous report has shown that 
sensory denervation of capsaicin-sensitive nerves by capsaicin, which 
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desensitizes TRPV1, increased glucose tolerance response to insulin 
(14), whereas another study suggested that glucose-stimulated insulin 
secretion is reduced in small rodents treated with capsaicin (17). 
TRPV1-null mice were protected against abnormal glucose and insulin 
resistance induced by HFD (15). In contrast, activation of TRPV1 by 
capsaicin enhanced glucose tolerance in mice fed HFD (18). Thus, it 
has been suggested in many studies that TRPV1 plays a critical role in 
obesity and diabetes however, whether TRPV1 functions as a repressor 
or promoter in the development of obesity and diabetes remains unclear. 
In the present study, we have demonstrated that TRPV1 
deletion exacerbates HFD-induced insulin resistance in WAT, BAT, 
and the heart. Indeed, insulin-stimulated phosphorylation of STAT3 in 
WAT was impaired in TRPV1 KO mice under HFD feeding for 5 
weeks. However, we could not detect any difference in the 
phosphorylation levels of Akt and STAT3 in the heart between HFD-
fed WT and TRPV1 KO mice, suggesting that further studies to 
elucidate the mechanisms of the pro-insulin resistance effects mediated 
by TRPV1 deletion is required. Taken together, our results suggest that 
TRPV1 may be a potential therapeutic target for obesity-related insulin 
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Deficiency of TRPV1 accelerates aging-induced 









Obesity as a major cause of insulin resistance promotes aging, 
which accerlerates obesity through a feedback response in various 
tissues including adipose tissues. Aging-induced obesity and insulin 
resistance have been clearly shown in animals and human. Although 
possible mechanism which involves in obesity-associated aging have 
been suggested by previous studies, it is still unclear. Transient receptor 
potential vanilloid subfamily type-1 (TRPV1) expression is remarkably 
decreased, which induces impaired pain sensing in aged mice and 
elderly human. With evidences indicating that TRPV1 involves in 
obesity and insulin resistance, I determined the effect of TRPV1 
deletion on aging-induced obesity and insulin resistance in vivo. 
Deficiency of TRPV1 accelerates aging-induced weight and fat mass 
gain by decreasing energy expenditure. In hyperinsulinemic-
euglycemic clamps, I found that TRPV1 deletion aggrevates aging-
induced insulin resistance, especially regulating hepatic insulin action. 
These results suggest that TRPV1 may be a promising therapeutic 
target for aing-induced metabolic disorders. 
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4.1. Introduction  
As changed lifestyle consuming more energy with less activity 
in these days, there has been a rise in aging-associated disorders such as 
cardiovascular disease, cancer, degenerative diseases, and metabolic 
diseases including obesity and diabetes(1). Obesity, a major cause of 
insulin resistance, and diabetes have been known to accerlarate aging, 
but the mechanisms connecting obesity, diabetes, and aging is not well 
studied. According to several reports, inflammation resulting from 
oxidative stress, DNA damage, and telomere dysfunction are associated 
in development metabolic diseases including obesity, diabetes, and 
atherosclerosis(2-4). Recently, the possible mechanisms supporting that 
aging accerlarates obesity and diabetes were supported by previous 
studies, suggesting involvement of mitochondria(5). Oxidative stress in 
mitochondria induces mitochondrial dysfunction, which promotes 
obesity and insulin resistance(6). In adipose tissue, especially, 
mitochondrial dysfunction which is a feature of normal aging triggers 
to high levels of oxidative stress and damaged cellular function 
involving in glucose metabolism and insulin sensitivity, promoting 
aging-associated diseases such as obesity and insulin resistance(5). 
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Besides, short telomere length strongly related to metabolic diseases 
such as cardiovascular disease and obesity has been known to lead 
abnormal fasting glucose/insulin, lipid and lipoprotein concentration, 
habitual physical activity, and other metabolic risk factors(7, 8). As a 
key regulator of aging, tumor suppressor protein 53 (p53) which 
prevent genome mutation during DNA damage induced by aging 
prevents obesity and insulin resistance by inhibiting pro-inflammatory 
response in the aging process of adipose tissue(9). However, some of 
them are found not to have no effect on aging-associated obesity in 
subjects according to sex or environmental factors(8). Thus, the 
specific mechanisms involving to aging-induced obesity and its-
associated disorders are fully understood, further studies are still 
needed. 
Transient receptor potential vanilloid subfamily type-1 
(TRPV1) has been reported to show strong association with aging. 
TRPV1 expression is decreased in sensory neuron of aged mice leading 
to loss of thermal sensitivity(10). Decreased pain sensitivity during 
aging in human and animal models is associated in reduction of TRPV1 
expression in peripheral nervous system (PNS) of aged mice(11). 
Therefore, these are supported that less or loss of TRPV1 activity 
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during aging may promotes aging-associated obesity and its-associated 
metabolic diseases. Previous report has been showed higher body 
weight in TRPV1-null mice with age (observed for up to 14 months), 
whereas the other study suggested protective effect of TRPV1 
deficiency in mice against weigth gain by 44 weeks of age(12, 13). 
These controversial results are strongly suggesting necessity of further 
studies to elucidate the role of TRPV1 on obesity and its-related 
disorders during aging.  
In present study, I found that TRPV1-deficient mice became 
spontaneously obese during aging by 9 months of age. This was caused 
by altered energy balance resulting from reduced VO2 consumption and 
energy expenditure in TRPV1-null mice. Aging-induced insulin 
resistance was shown to be severe in TRPV1-null, and insulin-
stimulated shutting down of hepatic glucose production (HGP) was 
completely impaired in TRPV1-deficient mice compared to WT mice. 
These results suggest that targeting TRPV1 could be a new strategy for 
the treatment obesity and insulin resistance induced by aging. 
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4.2. Materials and methods 
4.2.1. Animals 
TRPV1-deficient (TRPV1 KO) mice (n=4) and WT littermates 
(n=4) were purchased from Jackson Laboratory. 3-month-old mice 
were fed a chow deit ad libitum for 6 months. The animal studies were 
approved by the Institutional Animal Care and Use Committee of the 
University Massachusetts Medical School.  
4.2.2. Body composition  
Mice were housed under controlled temperature and lighting, 
with free access to food and water. Whole body fat and lean mass were 
noninvasively measured using 1H-MRS (Echo Medical Systems, 
Houston, TX).  
4.2.3. Energy balance measurement 
The food/water intake, energy expenditure, respiratory 
exchange ratio, and physical activity were assessed for 3 days using 
metabolic cages (TSE Systems, Chesterfield, MO). We used the TSE 
Systems LabMaster platform with easy-to-use calorimetry featuring 
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fully automated mon- itoring for food and water and XYZ activity. 
LabMaster cages that are most similar to facility home cages were used, 
thereby allowing the use of bedding in the cage and minimizing any 
animal anxiety during the experimental period. The system provides 
intuitive software with flexibility for experimental setup and data 
utilization. Rectal body temperature was measured in aged WT and 
TRPV1 KO mice. 
4.2.4. Hyperinsulinemic-euglycemic clamp 
At the age of 9 month in WT and TRPV1 KO mice, a survival 
surgery was performed at 4–5 days before clamp experiments to 
establish an indwelling catheter in jugular vein. On the day of 
experiment, mice were fasted overnight (~15 hrs), and a 2-hrs 
hyperinsulinemic euglycemic clamp was conducted in conscious mice 
with a primed and continuous infusion of human insulin (150 mU/kg 
body wt priming followed by 2.5 mU·kg-1 ·min-1, Humulin; Eli Lilly). 
To maintain euglycemia, 20% glucose was infused at variable rates 
during clamps. Whole body glucose turnover was assessed with a 
continuous infusion of [3-3H]glucose, and 2-deoxy-D-[1-14C]glucose 
(PerkinElmer) was administered as a bolus (10 µCi) at 75 min after the 
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start of the clamps to measure insulin-stimulated glucose uptake in 
individual organs. At the end of the clamps, mice were anesthetized, 
and tissues were taken for biochemical analysis(14). 
4.2.5. Biochemical analysis and calculation 
The glucose concentration during the clamps was analyzed 
using 10 µl plasma by a glucose oxidase method on a Beckman 
Glucose Analyzer 2 (Beckman, Fullerton, CA). Plasma concentrations 
of [3-3H]glucose, 2-deoxy-D-[1-14C]glucose, and 3H2O were 
determined after deproteinization of plasma samples as previously 
described(15). For the determination of tissue 2-deoxy-D-[1-
14C]glucose-6-phosphate content, tissue samples were homogenized, 
and the supernatants were subjected to an ion-exchange column to 
separate 2-deoxy-D-[1-14C]glucose-6-phosphate from 2-deoxy-D-[1-
14C]glucose. 
Rates of basal and insulin-stimulated whole-body glucose 
turnover were determined as the ratio of the [3H]glucose infusion rate 
(disintegrations per minute [dpm]) to the specific activity of plasma 
glucose (dpm/µmol) at the end of the basal period and during the final 
30 min of the clamps, respectively. Hepatic glucose production (HGP) 
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during the clamps was determined by subtracting the steady-state 
glucose infusion rate from the whole-body glucose turnover rate. 
Whole-body glycolysis and glycogen/lipid synthesis were calculated as 
previously described(15).  
4.2.6. Plasma leptin measurement 
The plasma levels of leptin were measured using ELISA kits 
(ALPCO Diagnostics, Salem, New Hampshire, USA). To collect 
plasma samples, mice were fasted for 5 hours in the morning. Using 
heparin-treated capillary tube, blood were collected carefully into the 
heparin-treated eppen tube, and centrifuged at 12,000rpm for 3 mins in 
4°C. For ELISA assay, supernant of centrifuged blood were used 
following the manufacturer’s instruction. 
4.2.7. Statistical analysis  
Data were expressed as mean ± S.E. values, and ANOVA was 
used for multiple statistical comparisons. A probability value of p< 
0.05 was used as the criterion for statistical significance. All analyses 




4.3.1. TRPV1 deficiency accelerates aging-induced obesity in mice 
To examine the effect of TRPV1 on aging-induced obesity, 
TRPV1 knockout (KO) mice and wild-type (WT) littermates fed chow 
diet ad libitum for 6 months and measured body composition at the 
beginning and end of experiment. Body weight of aged WT mice was 
significantly higher than yound WT mice (3 months of age), and aged 
TRPV1 KO mice became heavier than WT mice at 9 months of age 
(Figure 1A). Elevated accumulation of whole body fats of WT mice 
was also detected at the 9 months of age (Figure1B). Whole body fat 
mass was also significantly increased in aged TRPV1 KO mice 
compared to aged WT mice (Figure 1B). Interestingly, I found that 
aged TRPV1 KO mice had more lean mass than aged WT mice, 
suggesting possible involvement of other factors such as bone and 
muscle growth by TRPV1 deletion (Figure 1C). All of these data 
indicate that TRPV1 deletion aging-induced weight gain and obesity. 
 




Figure 1. TRPV1 deletion promotes on aging-induced weight gain and obesity in 
mice. (A) body weight was measured at 3 and 9 months of age (n=4, *P<0.05) in 
mice. (B and C) whole body fat and lean mass were measured weekly using 1H-MRS 
during experiment. WT, wild type C57BL/6J mice. KO, TRPV1 KO mice. P<0.05
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Since TRPV1 KO mice were more susceptible to aging-induced 
obesity than WT mice, I next examined the effect of TRPV1 deletion 
on energy balance using metabolic cage in TRPV1 KO and WT mice at 
the 3 months and 9 months of age. Food intake and physical activity 
were not altered in aged mice by TRPV1 deletion (Figure 2A and B). 
However, deficiency of TRPV1 changed indirect calorimetry such as 
VO2, VCO2, and energy expenditure normalized to whole body lean 
mass measured using 1H-MRS. In aged mice, VO2 consumption was 
increased by 11.2% and 6.7% compared to young WT and TRPV1 KO 
mice, respectively (Figure 3A). Aged TRPV1 mice showed remarkably 
decreased VO2 consumption compared to aged WT mice (Figure 3A). 
In Figure 3B, VO2 production were not different between young and 
aged WT mice (p=0.44) and young WT and TRPV1 KO mice (p=0.33). 
After 6 months, TRPV1 KO mice were significantly decreased VCO2 
production, which leads to reduce energy expenditure (Figure 3C). All 
of these data suggest that TRPV1 deletion promotes aging-associated 
reduction of VCO2 production, whereas VO2 consumption was 
increased in aged WT and TRPV1 KO mice, probably resulting from 
increased lean mass (Figure 1C), which trigger to reduce energy 




Figure 2. Deficiency of TRPV1 have no effect on food intake and physical 
activity during aging. (A) Daily food intake in WT and TRPV1 KO mice. (B) Total 
counts of beam break for measuring physical activity during nighttime.   
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energy expendutre in aged TRPV1 KO mice was not caused by 
decreased body temperature (Figure 3D). 
4.3.3. Deletion of TRPV1 promotes aging-induced insulin resistance  
Since aged TRPV1 KO mice showed obesity and less energy 
expenditure, I next examined the effect of TRPV1 deletion on aging-
associated insulin resistance using hyperinsulinemic-euglycemic clamp. 
It was clearly showed the defects of insulin sensitivity in aged (9 
months of age) WT mice compared to young (3 months of age) WT 
mice (Figure 4A). In addition, glucose infusion rate of aged TRPV1 
KO mice considerably lower than aged WT mice. Whole body glucose 
turnover rate and glycolysis, however, were not changed by TRPV1 
deletion in aged mice (Figure 4B and C). Because there are no 
difference in whole body glucose turnover rate, glycolysis, and 
consequently glycogen synthesis between aged WT and TRPV1 KO 
mice with showing impaired whole body insulin senstivity, I 
hypothesized that TRPV1 deficiency affects on hepatic glucose 
production and insulin action, which results in decreased glucose 




Figure 3. TRPV1 deletion induces reduction of energy expenditure during aging 
in mice. All data are expressed per kg of whole body lean mass measured using 1H-
MRS. (A and B) Average VO2 consumption (A) and VCO2 production (B). (C) 
Average energy expenditure rates. (D) Rectal body temperature measured at day time 




Figure 4. Deletion of TRPV1 promotes aging-induced whole body insulin 
resistance in mice. (A) Steady-state glucose infusion rate during hyperinsulinemic-
euglycemic clamp in conscious mice. (B) Insulin-stimulated whole body glucose 
turnover was calculated using [3H]glucose infusion during clamps. (C) Insulin-
stimulated whole body glycolysis was estimated by during clamps. P<0.05 
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4.3.4. Deletion of TRPV1 aggrevates aging-induced impaired 
insulin sensitivity in liver  
To further investigate how TRPV1 deletion exacerbates aging-
induced whole body insulin resistance, I checked the levels of hepatic 
glucose production and insulin action measured [3H]glucose from 
clamps. Insulin-stimulated reduction of hepatic glucose production was 
remarkably inhibited in TRPV1 KO mice compared to WT mice during 
clamps, whereas there is no difference in basal hepatic glucose 
production between WT and TRPV1 KO mice (Figure 5A). As a result, 
hepatic insulin action was significantly inhibited in aged TRPV1 mice 
compared to WT mice (Figure 5B), supporting decreased glucose 
infusion rate with no effect on whole body glucose turnover, glycogen 
synthesis, and glycolysis in aged TRPV1 KO mice. 
4.3.5. Deletion of TRPV1 have no effect on glucose uptake levels in 
adipose tissues, muscle, and heart  
To confirm the effect of TRPV1 deletion on aged-induced tissue 
specific insulin resistance, I performed glucose uptake assay by 
measured [3H]glucose in skeletal muscle, white adipose tissue, and  
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Figure 5. TRPV1 dificiency aggrevates aging-induced insulin resistance 
in liver. (A) Hepatic glucose production was estimated using [3H]glucose 
during clamps in aged WT and TRPV1 KO mice. Using basal and clamp HGP 
(A), hepatic insulin action (B) was calculated. P<0.05 
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heart using samples obtained at the end of the clamps. Insulin-
stimulated glucose uptake into white adipose tissue (Figure 6A) and 
muscle (Figre 6B). Grucose uptake rate were slightly reduced by 
TRPV1 deletion in brown adipose tissue (50% of reduction vs. aged 
WT mice, Figure 6C) and heart (31% of reduction vs. aged WT mice, 






Figure 6. Deletion of TRPV1 dose not affect on insulin resistance in adipose 
tissues, skeletal muscle, and heart during aging. Insulin-stimulated glucose uptake 
in white adipose tissue (A), brown adipose tissue m(B), skeletal muscle (C), and heart 
(D) were measured using [14C]glucose in aged WT and TRPV1 KO mice. P value 






Strong correlation between aging and obesity has been reported 
by a considerable amount of previous studies in a recent decade. 
Obesity accelerates aging of adipose tissue and skeletal muscle by 
inducing disruption of mitochondrial function, elevated DNA damage, 
and short telomere length(1, 9, 16, 17). Insulin resistance mainly 
caused by obesity is accelerated by inflammation, oxidative stress, and 
mitochondrial dysfunction(17-19). Since TRPV1 also involves in aging 
process by regulating pain and thermogenic sensitivity, it may play a 
crucial role in aging-associated obesity and insulin resistance. 
Here, I demonstrated that the deletion of TRPV1 aggravates 
aging-induced weight gain and fat accumulation. Interestingly, both 
aged WT and TRPV1 KO mice showed increased fat mass compared to 
young (3 months of age) WT and TRPV1 KO mice, respectively, which 
results from the increased muscle or bone mass in aged mice during 
this experiment for 6 months (Figure 1C). Although old rodents or 
elderly human showed decreased lean mass and physical activity 
because of degeneration of muscle and bone(20), I did not find any 
decrease of lean mass and physical activity in age WT mice. This 
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probably means that 9 months of age cannot fully induce aging in 
C57BL/6J mice (WT) a background strain of TRPV1 KO mice, and 
their muscle and bone were still growing and working normally. It is 
also possible that distinct regulation of TRPV1 on energy balance 
during aging affects complexly in mice. Since the mechanisms 
associated with TRPV1 in aging-induced obesity is very complicated, 
further studies to demonstrate cause of hypometabolism in TRPV1 KO 
mice during aging should be conducted. 
Aging-induced insulin resistance in WT mice was demonstrated 
in Figure 4A of the present study. Surprisingly, aged TRPV1-null mice 
showed almost completely stopped whole body insulin action during 
clamps, which suggests that TRPV1 plays an important role in 
development of insulin resistance during aging. As a primary target 
organ of TRPV1 deletion during aging-associated insulin resistance 
progression, liver totally did not respond to insulin stimulation in 
TRPV1 KO mice. This result is conflict with the data showing diet-
induced insulin resistance in adipose tissues and heart, but not in liver 
in TRPV1 KO mice fed high-fat diet from Chapter 3, which indicates 
the different mechanisms are involved in aging-associated insulin 
resistance from diet-induced impaired insulin sensitivity in TRPV1 KO 
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mice. Besides, several factors such as VCO2 production (p=0.09), 
brown adipose tissue and heart glucose uptake (p=0.095 and 0.13, 
respectively) between aged WT and TRPV1 KO mice did not have 
statistical significance, and 9 months of age was not enough to fully 
induce aging in this experiment, suggesting that further studies to 
increase number of mice used in experiment and sufficiently should be 
performed. 
Here, I demonstrated that TRPV1 deficiency promotes aging-
associated obesity and insulin resistance in mice. This is caused by 
reduced energy expenditure and inhibition of heptic insulin sensitivity 
by TRPV1 deletion. These results suggest that TRPV1 could be a 
promising therapeutic agent againt aging-associated obesity, insulin 
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5.1. Deterioration of diet-induced obesity and leptin 
resistance in TRPV1 deficient mice   
In the past few decades, the role and mechanism of capsaicin 
and transient receptor potential vanilloid type-1 (TRPV1) in metabolic 
diseases have been suggested. Consumption of red peppers or capsaicin 
was shown to decrease appetite, cause weight loss and stimulate 
thermogenesis caused by substrate oxidation from carbohydrate to fat 
oxidation(1-3). With these previous studies, deletion of TRPV1 
exacerbates diet-induced obesity characterized by higher fat mass and 
weight gain than wild-type (WT) littermates fed high-fat diet (HFD). 
The elevated obesity in TRPV1 knockout (KO) mice were caused by 
reduced locomotor activity without any changes in food intake and 
energy expenditure. Because activity is regulated by hypothalamic 
leptin signaling, responsiveness to leptin is a critical mediator of energy 
balance to maintain homeostasis. TRPV1 deficient mice were impaired 
in the leptin/activity or energy expenditure axis of hypothalamus so that 
these mice showed opposite correlation pattern between activity/energy 
expenditure vs. leptin level. In leptin infusion study, also, TRPV1 KO 
mice were leptin resistance characterized by no response of food intake 
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reduction to leptin compared to WT mice. Together, these results 
strongly suggest that increased weight gain and fat mass upon HFD in 
TRPV1 KO mice were due to, at least in part, to an decreased activity 
with elevated plasma leptin levels, which indicates leptin resistance in 
these mice. 
Capsaicin treatment inhibits differentiation of preadipocyte to 
adipocyte by regulating AMP-activated protein kinase (AMPK) and 
induces apoptosis and cell death in 3T3-L1 preadipocytes(4, 5). 
Repeated exposure to capsaicin (chronic) or exposure to high dose of 
capsaicin (acute) induces degradation of TRPV1 protein called as 
“desensitization”(6, 7). As a selective receptor of capsaicin, TRPV1 has 
been reported that it is expressed in preadipocytes and visceral adipose 
tissues both mice and humans(8), suggesting its possible role for 
biological process of adipocyte and adipogenesis. However, 
differentiation of primary cultured mouse embryonic fibroblasts 
(MEFs) from TRPV1 KO mice to adipocytes was markedly blocked 
compared to WT MEFs (data not shown), which is inconsistent with in 
vivo data showing increased fat accumulation in TRPV1 mice. This 
result suggests that deletion of TRPV1 affects on adipocyte 
differentiation, indicating that TRPV1 is required for normal 
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adipogenesis. Although TRPV1 deletion definitely promotes obesity 
and leptin resistance in mice, further studies to clarify mechanisms of 
TRPV1 involving obesity and leptin resistance were needed. In my 
study, I found that TRPV1 deletion influenced phosphorylation of 
STAT3 by leptin in primary cultured MEFs and hypothalamus of mice 
negatively, which induced blunt leptin signaling by TRPV1 deficiency. 
However, regulatory mechanism in TRPV1 deletion by leptin was still 
not fully understood. 
 
5.2. Deterioration of diet- and aging-induced obesity and 
insulin resistance in TRPV1 deficient mice 
Leptin resistance characterized by decreased sensitivity aginst 
leptin with hyperleptinemia is strongly correlated to obesity and its 
associated insulin resistance. TRPV1 deletion significantly reduced 
insulin sensitivity compared to WT littermates during HFD feeding. 
This result was also supported by decreased insulin-stimulated whole 
body glucose turnover in TRPV1 KO mice fed HFD for 5 weeks in 
Chapter 3. Among several insulin sensitive tissues, white and brown 
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adipose tissues and heart play critical roles in development of insulin 
resistance by TRPV1 deletion after HFD.  
Indeed, It has been widely known that HFD mainly promotes 
obesity and insulin resistance. As another cuase of obesity and insulin 
resistance, aging affects on obesity and insulin resistance. In adipocyte, 
especially, aging plays a crucial role in the development of adipocyte 
inflammation and insulin resistance through the elevated accumulation 
of macrophage and oxidative stress by regulating p53, which is a 
representative survival and aging factors(9). However, the mechanism 
how aging accelerates obesity and insulin resistance is not fully 
understood. Here, TRPV1 KO mice became more obese under aging 
condition having higher fat accumulation and even higher lean mass 
than WT mice. The elevated obesity of TRPV1 KO mice was caused by 
imbalance of energy homeostasis shown reduced energy expenditure 
without any changes in energy intake. Similarly, insulin signaling in 
aged TRPV1 mice almost shut down compared to age-matched WT 
mice, which suggest severe insulin resistance in aged TRPV1 mice 
showing reduced hepatic insulin sensitivity. Together, deficiency of 
TRPV1 aggravates diet- and aging-induced obesity and insulin 
resistance in vivo, which supports that activation of TRPV1 could be 
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Although the role of TRPV1 on diet- and aging-induced obesity 
and its associated metabolic abnormal condition such as leptin 
resistance and insulin resistance has been determined by present study, 
how and why TRPV1 regulates these metabolic diseases is still not 
fully understood. Also, the reason the results from this study are 
different from previous study reported anti-obesity effect in TRPV1 
KO mice which is same strain that I used in the experiments(10).  
There are several explainable reasons; HFD used in my study has 
different fat source and calories. In previous report(10), they used HFD 
containing 11% of fat (25.8% of calories provided by fat), which is 
comparable to chow diet. I used HFD containing 55% fat by calories, 
and usually HFD of 45-65% fat by calories have been used by various 
researchers. Also, the fat source is cocoa butter having high proportion 
of saturated fat in previous study(10), whereas HFD used in my study 
contains corn oil with 28% of saturated fat, 30% of trans, 28% of 
monounsaturated (cis), and 14% of polyunsaturated (cis)(11). In 
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addition, the duration fed HFD is different from my study. I fed HFD 
for 5 weeks in mice, whereas they fed HFD by 6 months(10). Because 
they fed HFD for considerably long time, it can be suggested the 
involvement of aging in their experiments. To exclude the effect of 
aging in TRPV1 KO mice, I just fed only for 5 weeks and carried out 
separate experiment which examined the effect of TRPV1 deletion on 
aging-induced obesity and insulin resistance to explain the effect of 
aging. These differences of diet and duration can be critical reasons to 
induce opposite results with previous study(10). 
As a down stream of insulin and leptin signaling, JAK/STAT3 
pathway plays a multiple and critical role in the development of obesity 
and leptin/insulin resistance. Phosphorylation of STAT3 on Tyr 705 
responds and activates transcription to various cytokines, which 
suggests it is a representative inflammatory marker. TRPV1 deletion 
was damaged in STAT3 pathway in response to leptin and insulin 
stimulation, which is caused by impaired suppressor of cytokine 
signaling 3 (SOCS3) expression in TRPV1 deleted MEFs and SOCS3 
(data not shown). These data supports that impaired STAT3 
phosphorylation was not directly altered by TRPV1 deletion, 
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suggesting the other molecular target mechanism of TRPV1 deletion by 
directly influencing these metabolic conditions. 
In chapter 3 and 4, TRPV1 deficient mice showed abnormally 
obese and insulin resistance phenotype compared to WT mice by HFD 
and aging. However, the responsible mechanisms for obesity and 
insulin resistance were thought to be quite different between diet- and 
aging-induced models. HFD induced disability of insulin signaling in 
white/brown adipose tissue and heart, but aging induced impaired 
hepatic insulin action in TRPV1 KO mice. In addition, TRPV1 deletion 
mice had less energy expenditure by aging-induced obesity, whereas 
they became hypoactive during HFD feeding. These phenomena 
strongly suggest that mechanistic process induced by aging to develop 
obesity and insulin resistance is quite different between by diet. 
Although failure of improvement of weight loss in Capsaicin 
treatment in mice (data not shown), Capsaicin induces leptin sensitivity 
characterized by reduced food intake with similar amount of plasma 
leptin levels to vehicle-treated group in chapter 2. Also, deficiency of 
TRPV1 promotes obesity and leptin/insulin resistance in mice (Figure 
1), indicating that activation of TRPV1 by capsaicin should be a gold 




Figure 1. Possible mechanisms of TRPV1 on diet- and aging-





Moreover, these results provide new insight into the involvement of 
TRPV1 as a capsaicin receptor in the development of obesity and its-
associated metabolic disorders and strategy against their pathogenesis 
as a therapeutic target. 
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비만이 전세계적으로 만연함에 따라 비만 및 그와 
연관된 대사성 질환이 심각한 질병으로 떠오르고 있다. 본 
연구에서는 캡사이신 수용체인 TRPV1 의 비만 및 대표적인 
이형 당뇨의 지표로서 인슐린 저항성에 미치는 영향을 마우스 
모델을 활용하여 밝히고자 하였다. 5 주간 고지방 식이를 
투여함으로 인하여 유도되는 체중 증가와 지방 축적이 
TRPV1 결핍 마우스에서 더욱 악화되어 나타나는 것을 
확인하였으며, 이러한 비만의 악화는 TRPV1 결핍 
마우스에서의 감소된 육체활동으로 인한 것임을 알 수 있었다. 
육체활의 감소를 유도할 수 있는 상위 인자로 렙틴을 확인한 
결과, 혈중 렙틴의 증가에 의하여 움직임과 에너지 소비량이 
증가하고 에너지 섭취량이 감소해야 함에도 불구하고 TRPV1 
결핍 마우스에서는 이러한 조절이 정 반대의, 비정상적인 
패턴을 보이는 렙틴 저항성이 나타남을 확인하였다. 따라서 본 
연구에서는 TRPV1 이 결핍되어 있는 경우에 고지방 식이로 
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유도되는 비만 및 렙틴 저항성이 악화됨을 통하여 TRPV1 이 
고지방 식이에 의한 비만 및 렙틴 저항성 치료에 효과적인 
목표가 될 수 있음을 보여주었다. 또한 TRPV1 결핍은 고지방 
식이로 유도되는 인슐린 저항성을 더욱 악화시키며 이러한 
것이 지방세포와 심장에서의 감소한 인슐린 민감성에 의한 
것임을 증명하였다. 
노화는 염증과 산화적 스트레스, 미토콘드리아의 기능 
장애의 주요 원인 중 하나로 선행연구에 따르면 비만과 
인슐린 저항성을 유발함으로서 당뇨 및 대사성 질환으로의 
진행을 유도한다고 보고되어 있다. TRPV1 이 결핍된 마우스는 
노화로 유도되는 체중 증가 및 지방, 제지방량 증가가 더욱 큰 
폭으로 나타나며 인슐린 저항성 또한 악화됨을 확인하였다. 
고지방식이로 유도되는 모델과는 달리, 노화로 유도되는 
인슐린 저항성에 있어서 TRPV1 의 결핍은 간에서의 인슐린 
활성을 현저히 감소시킴으로서 전체적인 인슐린 저항성을 
유도함을 확인하였다. 따라서 본 연구결과를 통하여 TRPV1 이 
비만 및 에너지 밸런스, 렙틴 저항성 및 인슐린 저항성의 발생 
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과정에 관여하는 중요한 조절자로서, 비만과 이형 당뇨를 
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